Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yujing Tan

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Frontiers in Immunology|July 3, 2025
Case Report: Hepatic sarcoidosis-like reaction from neoadjuvant pembrolizumab in early-stage triple-negative breast cancerYujing Tan, Yu Wang, Xiaoyan Liu, et al.
BMC Microbiology|March 8, 2025
Characterization of a novel lytic phage vB_AbaM_AB4P2 encoding depolymerase and its application in eliminating biofilms formed by Acinetobacter baumanniiJianhui Su, Yujing Tan, Shenshen Liu, et al.
ACS Biomaterials Science & Engineering|January 15, 2021
Amino-Acid-Incorporating Nonionic Surfactants for Stabilization of Protein PharmaceuticalsJoshua S Katz, Yujing Tan, Krishna Kuppannan, et al.
BMC Microbiology|February 12, 2025
Discovery, structural characteristics and evolutionary analyses of functional domains in Acinetobacter baumannii phage tail fiber/spike proteinsShenshen Liu, Tao Lei, Yujing Tan, et al.
Breast Cancer (Dove Medical Press)|January 29, 2025
Non-Luminal Disease Score for Everolimus in Patients with Hormone Receptor‑positive and Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Multicenter and Retrospective StudyYujing Tan, Hanfang Jiang, Xinzhu Tian, et al.
Cancer Research and Treatment|January 14, 2026
Pre-Treatment Ki67 Index for Everolimus Efficacy in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Multicenter Cohort StudyYujing Tan, Hanfang Jiang, Fei Ma, et al.
Thoracic Cancer|November 8, 2023
Efficacy of everolimus-based therapy in advanced triple-positive breast cancer: Experience from three cancer centers in ChinaYujing Tan, Hanfang Jiang, Fei Ma, et al.
BMC Cancer|January 25, 2024
Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastomaYinghao Lu, Limin Liao, Kunpeng Du, et al.
Medcomm|December 1, 2025
High-Plex Digital Spatial Profiling Identified Prolactin-Induced Protein mRNA Associated With Response and Survival of Everolimus and Letrozole Treatment for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerYuhang Han, Danyang Ji, Yujing Tan, et al.
Therapeutic Advances in Medical Oncology|November 18, 2024
Everolimus treatment in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer and a predictive model for its efficacy: a multicenter real-world studyYujing Tan, Zexi Peng, Hanfang Jiang, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Frontiers in Immunology|July 3, 2025
Case Report: Hepatic sarcoidosis-like reaction from neoadjuvant pembrolizumab in early-stage triple-negative breast cancerYujing Tan, Yu Wang, Xiaoyan Liu, et al.
BMC Microbiology|March 8, 2025
Characterization of a novel lytic phage vB_AbaM_AB4P2 encoding depolymerase and its application in eliminating biofilms formed by Acinetobacter baumanniiJianhui Su, Yujing Tan, Shenshen Liu, et al.
ACS Biomaterials Science & Engineering|January 15, 2021
Amino-Acid-Incorporating Nonionic Surfactants for Stabilization of Protein PharmaceuticalsJoshua S Katz, Yujing Tan, Krishna Kuppannan, et al.
BMC Microbiology|February 12, 2025
Discovery, structural characteristics and evolutionary analyses of functional domains in Acinetobacter baumannii phage tail fiber/spike proteinsShenshen Liu, Tao Lei, Yujing Tan, et al.
Breast Cancer (Dove Medical Press)|January 29, 2025
Non-Luminal Disease Score for Everolimus in Patients with Hormone Receptor‑positive and Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Multicenter and Retrospective StudyYujing Tan, Hanfang Jiang, Xinzhu Tian, et al.
Cancer Research and Treatment|January 14, 2026
Pre-Treatment Ki67 Index for Everolimus Efficacy in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Multicenter Cohort StudyYujing Tan, Hanfang Jiang, Fei Ma, et al.
Thoracic Cancer|November 8, 2023
Efficacy of everolimus-based therapy in advanced triple-positive breast cancer: Experience from three cancer centers in ChinaYujing Tan, Hanfang Jiang, Fei Ma, et al.
BMC Cancer|January 25, 2024
Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastomaYinghao Lu, Limin Liao, Kunpeng Du, et al.
Medcomm|December 1, 2025
High-Plex Digital Spatial Profiling Identified Prolactin-Induced Protein mRNA Associated With Response and Survival of Everolimus and Letrozole Treatment for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerYuhang Han, Danyang Ji, Yujing Tan, et al.
Therapeutic Advances in Medical Oncology|November 18, 2024
Everolimus treatment in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer and a predictive model for its efficacy: a multicenter real-world studyYujing Tan, Zexi Peng, Hanfang Jiang, et al.
Pageof 5